

# Pipeline Update: Anticipated Generic Approvals/Launches/Patent 2016

Trade Name (generic name) Company(ies)	Therapeutic Use(s)	Estimated U.S. Sales†	Anticipated Generic Availability	Anticipated Generic Launch Type
Benicar (Olmesartan)	Hypertension	\$2.6 billion	10/25/2016	Exclusive
Seroquel XR (Quetiapine)	Bipolar, Schizophrenia	\$1.25 billion	11/1/2016	Exclusive
Tamiflu (Oseltamivir)	Influenza A and B	\$800 million	12/12/2016	Exclusive
Zetia (Ezetimibe)	Hypercholesterolemia	\$2.6 billion	12/12/2016	Exclusive
Epi-Pen (Epinephrine)	Anaphylaxis	\$1.1 billion	2H 2016	Exclusive
Welchol (colesevelam hydrochloride)	Primary Hyperlipidemia; Type 2 Diabetes Mellitus	\$574 million	2H 2016	Exclusive

†Financial data compiled from available annual and quarterly pharmaceutical company reports, IMS Health, BioMedTracker, Thomson Cortellis, analyst reports, and company press releases.

FDA approval; Exclusive = Denotes that one generic manufacturer will be eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval. Typically, the exclusive generic manufacturer will be eligible for a 180-day period of marketing exclusivity beginning either from the date it begins commercial marketing of the generic drug product, or from the date of a court decision finding the patent invalid, unenforceable or not infringed, whichever is first.